DK0773781T3 - Faststofadministrationssystemer til styret afgivelse af deri inkorporerede molekyler samt fremgangsmåder til fremstilling af sådanne systemer - Google Patents

Faststofadministrationssystemer til styret afgivelse af deri inkorporerede molekyler samt fremgangsmåder til fremstilling af sådanne systemer

Info

Publication number
DK0773781T3
DK0773781T3 DK95927856T DK95927856T DK0773781T3 DK 0773781 T3 DK0773781 T3 DK 0773781T3 DK 95927856 T DK95927856 T DK 95927856T DK 95927856 T DK95927856 T DK 95927856T DK 0773781 T3 DK0773781 T3 DK 0773781T3
Authority
DK
Denmark
Prior art keywords
systems
producing
solid
methods
controlled release
Prior art date
Application number
DK95927856T
Other languages
Danish (da)
English (en)
Inventor
Julian Alexander Landcli Blair
Bruce Joseph Roser
Camilo Colaco
Mohamed Abdel Zahra Jerrow
Jaap Kampinga
James Lewis Wardell
John Alistair Duffy
Original Assignee
Elan Drug Delivery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26305403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0773781(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB9415810A external-priority patent/GB9415810D0/en
Priority claimed from US08/349,029 external-priority patent/US6290991B1/en
Application filed by Elan Drug Delivery Ltd filed Critical Elan Drug Delivery Ltd
Application granted granted Critical
Publication of DK0773781T3 publication Critical patent/DK0773781T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Detergent Compositions (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Lubricants (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK95927856T 1994-08-04 1995-08-04 Faststofadministrationssystemer til styret afgivelse af deri inkorporerede molekyler samt fremgangsmåder til fremstilling af sådanne systemer DK0773781T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9415810A GB9415810D0 (en) 1994-08-04 1994-08-04 Composition
US08/349,029 US6290991B1 (en) 1994-12-02 1994-12-02 Solid dose delivery vehicle and methods of making same
PCT/GB1995/001861 WO1996003978A1 (en) 1994-08-04 1995-08-04 Solid delivery systems for controlled release of molecules incorporated therein and methods of making same

Publications (1)

Publication Number Publication Date
DK0773781T3 true DK0773781T3 (da) 2004-02-16

Family

ID=26305403

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95927856T DK0773781T3 (da) 1994-08-04 1995-08-04 Faststofadministrationssystemer til styret afgivelse af deri inkorporerede molekyler samt fremgangsmåder til fremstilling af sådanne systemer

Country Status (20)

Country Link
EP (4) EP1516615A3 (pl)
JP (2) JPH10503769A (pl)
CN (1) CN1152670C (pl)
AT (1) ATE252373T1 (pl)
BG (1) BG101278A (pl)
CA (1) CA2197982C (pl)
CZ (1) CZ297431B6 (pl)
DE (1) DE69531992T2 (pl)
DK (1) DK0773781T3 (pl)
EE (1) EE03593B1 (pl)
ES (1) ES2208687T3 (pl)
FI (1) FI970867L (pl)
HU (1) HUT77777A (pl)
MX (1) MX9701394A (pl)
NO (1) NO326966B1 (pl)
NZ (1) NZ290896A (pl)
PL (1) PL184068B1 (pl)
PT (1) PT773781E (pl)
SK (1) SK283026B6 (pl)
WO (1) WO1996003978A1 (pl)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE220327T1 (de) 1992-09-29 2002-07-15 Inhale Therapeutic Syst Pulmonale abgabe von aktiven fragmenten des parathormons
ES2218543T3 (es) 1994-03-07 2004-11-16 Nektar Therapeutics Procedimiento y preparacion para la administracion de insulina por via pulmonar.
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
CZ88697A3 (en) 1994-09-22 1997-09-17 Quadrant Holdings Cambridge Composition used for re-hydration and nourishment in the course of athletic outputs and processes for preparing thereof
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
GB9508691D0 (en) 1995-04-28 1995-06-14 Pafra Ltd Stable compositions
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
ZA9711732B (en) * 1996-12-31 1998-12-28 Quadrant Holdings Cambridge Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery
GB9705588D0 (en) * 1997-03-18 1997-05-07 Anglia Research Foundation Stable particle in liquid formulations
ES2187038T3 (es) * 1997-07-03 2003-05-16 Elan Drug Delivery Ltd Glicosidos modificados, composiciones que los comprenden y procedimientos para su utilizacion.
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6352722B1 (en) 1997-12-23 2002-03-05 Quadrant Holdings Cambridge Limited Derivatized carbohydrates, compositions comprised thereof and methods of use thereof
DE69900746T2 (de) * 1998-01-30 2002-08-14 Scios Inc., Mountain View Gesteuerte verabreichung von peptiden oder proteinen
US6455096B1 (en) * 1998-04-28 2002-09-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Hard candy with a relatively-high moisture and hardness, and process of the same
RU2165264C2 (ru) * 1998-07-10 2001-04-20 Бичурина Маина Александровна Фармацевтическая композиция для лечения герпеса
AU5751799A (en) * 1998-09-09 2000-03-27 Quadrant Holdings Cambridge Limited Filamentous amorphous carbohydrate compositions and therapeutic delivery vehicles comprising them
JP2002542183A (ja) 1999-04-16 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 成形可能な乾燥した医薬製剤
GB9916316D0 (en) 1999-07-12 1999-09-15 Quadrant Holdings Cambridge Dry powder compositions
US8632785B2 (en) 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
JP2003522154A (ja) * 2000-02-08 2003-07-22 アラーガン、インコーポレイテッド ボツリヌス毒素医薬組成物
JP3419729B2 (ja) * 2000-03-16 2003-06-23 株式会社ファンケル 錠剤およびその製造方法
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7442388B2 (en) 2000-05-10 2008-10-28 Weers Jeffry G Phospholipid-based powders for drug delivery
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
GB0017999D0 (en) * 2000-07-21 2000-09-13 Smithkline Beecham Biolog Novel device
GB0020616D0 (en) * 2000-08-21 2000-10-11 Quadrant Holdings Cambridge Particulates
EP1452171B1 (en) * 2000-10-13 2009-12-02 Cambridge Biostability Limited Pharmaceutical liquid suspensions
EP1333880B1 (en) 2000-10-26 2009-04-15 Alza Corporation Transdermal drug delivery devices having coated microprotrusions
US6623762B2 (en) * 2001-02-16 2003-09-23 Cambridge Biostability Ltd. Composition and method for controlled release injections
ES2333849T3 (es) * 2001-04-20 2010-03-02 Alza Corporation Disposicion de microsalientes que presenta un revestimiento que contiene un agente beneficioso.
GB0124710D0 (en) * 2001-10-15 2001-12-05 Quadrant Healthcare Uk Ltd Therapeutic composition
TW200300696A (en) 2001-11-01 2003-06-16 Inhale Therapeutic Syst Spray drying methods and related compositions
DE10157124A1 (de) * 2001-11-21 2003-05-28 Lohmann Therapie Syst Lts Mikrofaserhaltige Vorrichtung zur kontrollierten Freisetzung von Stoffen
US8454997B2 (en) 2001-12-18 2013-06-04 Novo Nordisk A/S Solid dose micro implant
US7368102B2 (en) 2001-12-19 2008-05-06 Nektar Therapeutics Pulmonary delivery of aminoglycosides
CA2473717A1 (en) * 2002-01-25 2003-07-31 Glaxo Group Limited Dna dosage forms
GB0201736D0 (en) * 2002-01-25 2002-03-13 Glaxo Group Ltd DNA dosage forms
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
GB0210771D0 (en) * 2002-05-10 2002-06-19 Univ London Pharmacy Derivatised particulate inhalation carriers
EP1428526A1 (en) * 2002-12-13 2004-06-16 Rijksuniversiteit Groningen Formulation for fast dissolution of lipophilic compounds
BRPI0412029A (pt) 2003-06-30 2006-09-05 Alza Corp formulações para microprojeções revestidas contendo contra-ìons não-voláteis
JP2009513531A (ja) * 2003-07-11 2009-04-02 グラクソ グループ リミテッド 糖エステルを含む吸入可能医薬製剤
GB0327727D0 (en) * 2003-11-28 2003-12-31 Quadrant Drug Delivery Ltd Viral microparticles
CA2566079A1 (en) 2004-05-12 2005-12-01 Terrence L. Scott Nucleic acid microspheres, production and delivery thereof
WO2005112885A2 (en) 2004-05-12 2005-12-01 Baxter International Inc. Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
JP5007427B2 (ja) 2004-05-13 2012-08-22 アルザ コーポレイション 副甲状腺ホルモン剤の経皮送達のための装置および方法
JP4547994B2 (ja) * 2004-06-02 2010-09-22 救急薬品工業株式会社 塊状物質含有積層フィルム状の可食性口腔内投与剤の製造方法および塊状物質含有積層フィルム状の可食性口腔内投与剤
TW200621310A (en) * 2004-11-10 2006-07-01 Univ Groningen A process for preparing formulations of lypophilic active substances by spray freeze drying
US20070009564A1 (en) 2005-06-22 2007-01-11 Mcclain James B Drug/polymer composite materials and methods of making the same
EP1933867A1 (en) 2005-10-04 2008-06-25 Alk-Abello A/S Solid vaccine formulation
JP2009522288A (ja) 2005-12-28 2009-06-11 アルザ コーポレイション 安定な治療剤形
EP1832281A1 (en) 2006-03-10 2007-09-12 Abbott GmbH & Co. KG Process for producing a solid dispersion of an active ingredient
US7871399B2 (en) 2006-05-17 2011-01-18 Alcon Research, Ltd. Disposable ophthalmic injection device
US20070270750A1 (en) 2006-05-17 2007-11-22 Alcon, Inc. Drug delivery device
US7811252B2 (en) 2006-05-17 2010-10-12 Alcon Research, Ltd. Dosage control device
US7674243B2 (en) 2006-05-17 2010-03-09 Alcon Inc. Ophthalmic injection device using piezoelectric array
US7862540B2 (en) 2006-05-17 2011-01-04 Alcon Research, Ltd. Ophthalmic injection device using shape memory alloy
US7887521B2 (en) 2006-05-17 2011-02-15 Alcon Research, Ltd. Ophthalmic injection system
US9022970B2 (en) 2006-10-16 2015-05-05 Alcon Research, Ltd. Ophthalmic injection device including dosage control device
US20080281292A1 (en) 2006-10-16 2008-11-13 Hickingbotham Dyson W Retractable Injection Port
JP2010510327A (ja) * 2006-11-21 2010-04-02 ジャイナ ファーマシューティカルズ，インコーポレーテッド エンドキシフェンの方法および組成物
GB2446780A (en) * 2007-02-22 2008-08-27 Glide Pharmaceutical Technolog An elongate parenteral injection body having an injection point of angle 10 to 40 degrees.
US7740619B2 (en) 2007-08-01 2010-06-22 Alcon Research, Ltd. Spring driven ophthalmic injection device with safety actuator lockout feature
US7629768B2 (en) 2007-08-03 2009-12-08 Alcon Research, Ltd. Easy cleaning C-shaped charging base
US8372036B2 (en) 2009-05-06 2013-02-12 Alcon Research, Ltd. Multi-layer heat assembly for a drug delivery device
GB0918450D0 (en) 2009-10-21 2009-12-09 Innovata Ltd Composition
US8177747B2 (en) 2009-12-22 2012-05-15 Alcon Research, Ltd. Method and apparatus for drug delivery
US9271899B2 (en) * 2010-04-30 2016-03-01 Allovate, Llc Methods, articles and kits for allergic desensitization, via the oral mucosa
EP2397484A1 (en) * 2010-06-11 2011-12-21 Immunovo B.V. Trisaccharide derivates, and their use as adjuvants
CA2853112C (en) 2011-10-25 2018-08-21 Onclave Therapeutics Limited Antibody formulations and methods
KR101574760B1 (ko) 2013-11-13 2015-12-04 주식회사 엘지생활건강 흡수속도를 개선한 마이크로니들 시스템
US20160310412A1 (en) 2013-12-16 2016-10-27 Takeda Pharmaceutical Company Limited Microneedle
US11273127B2 (en) 2014-05-06 2022-03-15 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for thermally stable multi-targeted antigens
US10182939B2 (en) 2015-09-16 2019-01-22 Novartis Ag Hydraulic injector and methods for intra-ocular lens insertion
RU2709464C2 (ru) 2015-09-29 2019-12-18 Кимберли-Кларк Ворлдвайд, Инк. Синергическая композиция для сохранения здорового баланса микрофлоры
KR102114993B1 (ko) * 2015-10-15 2020-05-25 주식회사 파이안에스테틱스 폴리펩타이드 및/또는 세포 배양 여액을 함유하는 수용성 스크럽 입자를 포함하는 화장제 조성물
GB2545880A (en) 2015-10-20 2017-07-05 Glide Pharmaceutical Tech Ltd Solid formulation
US10751408B2 (en) 2016-02-23 2020-08-25 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens
US12029748B2 (en) 2017-02-28 2024-07-09 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora
IT201700101582A1 (it) * 2017-09-12 2019-03-12 Milano Politecnico Dispositivo per rilascio intraoculare
WO2023077447A1 (zh) * 2021-11-05 2023-05-11 中国科学院过程工程研究所 环肽玻璃及含有环肽的药物组合物玻璃
CN116942592A (zh) * 2023-05-05 2023-10-27 中国科学院过程工程研究所 一种水溶性生物分子玻璃微针及制备方法
WO2025205239A1 (ja) * 2024-03-28 2025-10-02 株式会社トクヤマ 組成物、乾燥試薬、及び組成物を保存する方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1080265B (de) * 1958-09-30 1960-04-21 Bayer Ag Verfahren zur Herstellung von oral anzuwendenden Arzneimittel-zubereitungen mit protrahierter Wirkung aus Wirkstoffen und Schutzstoffen
GB981372A (en) * 1960-05-04 1965-01-27 Pfizer Ltd Pharmaceutical formulations for oral administration to animals
ATE68524T1 (de) 1985-07-09 1991-11-15 Quadrant Bioresources Ltd Beschuetzung von proteinen und aehnlichem.
US4855326A (en) * 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
JPH01288023A (ja) * 1988-05-16 1989-11-20 Nec Corp ミリ波構内無線通信方式
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
AU5414990A (en) 1989-04-12 1990-11-05 Aberdeen University Slow release vitreous systems
US5079018A (en) * 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
GB9009390D0 (en) * 1990-04-26 1990-06-20 Smith Kline French Lab Pharmaceutical compositions
GB9010742D0 (en) * 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
DK0615438T3 (da) * 1991-12-05 1996-11-11 Mallinckrodt Veterinary Inc En carbohydratglasmatrix til langvarig frigivelse af et terapeutisk middel
DK42093D0 (da) * 1993-04-07 1993-04-07 Bukh Meditec Administrationsmetode
TW360548B (en) * 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use

Also Published As

Publication number Publication date
SK27797A3 (en) 1997-08-06
HUT77777A (hu) 1998-08-28
CN1152670C (zh) 2004-06-09
EP0773781B1 (en) 2003-10-22
EP1138319A3 (en) 2003-03-19
FI970867A0 (fi) 1997-02-28
DE69531992T2 (de) 2004-07-22
EP1516615A3 (en) 2007-10-31
EP1138337A2 (en) 2001-10-04
FI970867A7 (fi) 1997-04-08
WO1996003978A1 (en) 1996-02-15
EP0773781A1 (en) 1997-05-21
MX9701394A (es) 1998-03-31
SK283026B6 (sk) 2003-02-04
PL184068B1 (pl) 2002-08-30
AU688557B2 (en) 1998-03-12
PT773781E (pt) 2004-03-31
ATE252373T1 (de) 2003-11-15
FI970867L (fi) 1997-04-08
BG101278A (bg) 1997-12-30
NZ290896A (en) 1997-04-24
EE9700062A (et) 1997-08-15
AU3185195A (en) 1996-03-04
NO971688L (no) 1997-04-11
CA2197982A1 (en) 1996-02-15
ES2208687T3 (es) 2004-06-16
DE69531992D1 (de) 2003-11-27
NO971688D0 (no) 1997-04-11
PL318898A1 (en) 1997-07-21
EP1138319A2 (en) 2001-10-04
NO326966B1 (no) 2009-03-23
JP2006056898A (ja) 2006-03-02
EP1516615A2 (en) 2005-03-23
CN1204959A (zh) 1999-01-13
CZ297431B6 (cs) 2006-12-13
EP1138337A3 (en) 2003-03-26
JPH10503769A (ja) 1998-04-07
EE03593B1 (et) 2002-02-15
CA2197982C (en) 2010-03-23
CZ47697A3 (en) 1997-08-13

Similar Documents

Publication Publication Date Title
EE03593B1 (et) Molekulide reguleeritud vabastamisega tahked manustamissüsteemid ja nende valmistamismeetodid
WO1997046204A3 (en) Injectable compositions
DE69812711D1 (de) Kohlenhydraten verwendbar in feste verabreichungssysteme
BRPI9809791B8 (pt) compostos imuno efetores de fosfato de aminoalquil glucosamina e composições compreendendo os mesmos
PE20001307A1 (es) Estructuras absorbentes de fibras celulosicas tratadas quimicamente
BR0214449A (pt) Agente absorvente de água, processo para produzir o mesmo e absorvedores e artigos absorventes fabricados com o agente absorvente de água
ES2046300T3 (es) Composicion para el tratamiento de la piel.
ES2074050T3 (es) Sistema de liberacion.
TR26920A (tr) Kisa ya da uzun elyafa dönüstürülmek üzere amaclanmis cam hazirlama yöntemi.
DK0490077T3 (da) Antisense-oligonukleotider til behandling af cancer
PT86138A (pt) Processo para a activacao transdermica ou topica utilizando um sistema terapeutico transdermico activado pelo utente
EP1106189A3 (en) Photo-curing tissue adhesive
DE69526228D1 (de) Regioselektive sulfatierung
BR0010769A (pt) Sistema de injeçao hipodérmica
NO174715C (no) Alkylakrylat/metakrylatkopolymer og fremgangsmåte til fremstilling derav samt anvendelse av upolymeriserbar alifatisk alkohol eller höytkokende, alifatisk hydroksyforbindelse som ultrafiolett-stabilisator i polymeren
BR8103992A (pt) Composicao adequada para o uso e processo para o tratamento de fibras de vidro ,fibra de vidro e composto de resina de poliester insaturada
WO2002036600A3 (en) Derivatised carbohydrates and their use in solid delivery systems
Aly et al. Conjunctival autografting technique for the management of primary pterygium
JIANG et al. Clinical Efficacy of Shenqi Fuzheng Injection Combined with Chemotherapy on Advanced Lung Cancer
WANG et al. The inhabitative effect of clonidine on the somatosensory evoked cerebral potential
LU et al. Effect of cognitive intervention on the chronic prostatitis following sexually transmitted diseases
FR2610573B1 (fr) Dispositif autorisant la pose rapide notamment d'elements de vitrage de vehicules tels que pare-brise
GUO et al. Study on the relationship between complement activation and inflammatory reaction in tissues of the perihematoma in patients with intracerebral hemorrhage
KR960000212A (ko) 친수성 고분자 물질을 함유하는 소수성 고분자 매트릭스를 이용한 경구용 약물 전달 체계
OM et al. Kinetics of degradation of flucloxacillin in different solutions and in the presence of some intravenous components